Skip to content

ORCA Study: Osteoarthritis and Risks Associated With the Consumption of NSAIDs

ORCA Study: Osteoarthritis and Risks Associated With the Consumption of NSAIDs

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04099459
Acronym
ORCA
Enrollment
1250
Registered
2019-09-23
Start date
2019-06-10
Completion date
2024-07-31
Last updated
2019-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

Cross-sectional epidemiological study in patients with diagnosis of osteoarthritis (OA) in order to evaluate risk factors associated with the use / prescription of non-steroidal anti-inflammatory drugs (NSAID).

Detailed description

OBJECTIVE: To evaluate the presence of risk factors associated with the use / prescription of non-steroidal anti-inflammatory drugs (NSAID) in patients diagnosed with osteoarthritis (OA). MATERIALS AND METHODS: A multicentric, cross-sectional epidemiological study, will be carried out in patients ≥ 38 years of age, with a previous diagnosis of primary or secondary OA, according to criteria of the American College of Rheumatology (ACR). The presence of at least one risk factor for the use / prescription of NSAIDs is the main variable. The secondary variables to be evaluated include: Demographical characterization of the patients, current disease status (level of pain and functional limitation), treatment (s) used (related or not to OA) and events side effects associated with the treatment (s). The analysis will be carried out from two perspectives: A first descriptive approach and a second analytical approach.

Interventions

None listed

Sponsors

Scandinavia Pharma
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
38 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 38 years * Previous diagnosis of OSTEOARTRITIS (primary or secondary) at least 30 days before or more, in at least one or more of the following locations: Knee and / or Hip and / or Hand, according to criteria of the American College of Rheumatology (ACR)

Exclusion criteria

* Refusal to participate in the study by the patient. * Patients who, in the judgment of the Investigator, do not understand or are not willing to adequately answer to the questions. * Mental or psychiatric illness that, in the judgment of the investigator, does not allow adequate information to be obtained.

Design outcomes

Primary

MeasureTime frameDescription
Presence of risk factors for adverse events associated to consumption of NSAIDsIt will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 yearsA descriptive analysis about presence of risk factors for the possible ocurrence of adverse events associated to consumption of NSAIDs in the patients: gastrointestinal, renal, cardiovascular.

Secondary

MeasureTime frameDescription
Demographic analysisIt will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 yearsCharacterization of patients
List of drugs used (by the patient) for treatment of osteoarthritis (OA)It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 yearsList of drugs used (by the patient) for treatment of osteoarthritis (OA), including time of use and posology.
Evaluation of the current state of the disease according to functional limitation and painIt will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 yearsEvaluation of functional limitation and pain according to the Visual Analogue Scale graduated between 0 and 10, being 0 absence or asymptomatic and 10 the maximum pain or maximum functional limitation.
Adverse Events related with the treatmentsIt will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 yearsEvaluation of Adverse events associated with the treatment (s)

Countries

Colombia

Contacts

Primary ContactJavier Castillo, Dr
jcastill@scandinavia.com.co+571-6461700
Backup ContactClaudio Ferrari, Dr
cferrari@scandinavia.com.co+571-6461700

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026